Phase II Trial of Bevacizumab, Radiation Therapy and Temodar Followed by Bevacizumab and Temodar With Continuation of Bevacizumab Beyond Progression (BBP-Bevacizumab Beyond Progression)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Bevacizumab (Primary) ; Antineoplastics; Temozolomide
- Indications Glioblastoma; Gliosarcoma
- Focus Therapeutic Use
- Acronyms BBP
- 02 Jun 2017 Results assessing relation between tumour progression and exercise behaviour presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 27 Jan 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2019.
- 27 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2019.